arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

biote Corp.

BTMD
$1.48 ▼ -0.11 (-6.92%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
22 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Moderately Bearish
auto_awesome

Analytical Summary

biote Corp. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $45.4M
Dividend Yield
Revenue Growth -8.3%
Op. Margin 7.0%
ROIC 5.6%
FCF / Share $0.12
Trailing P/E 21.1x
Price / Book
FCF Yield 7.8%
Debt / Equity -1.81
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.94M
↓ -8.3%
Net Income Profit after all expenses
$2.28M
↓ -83.4%
Operating Margin Operating profit as % of sales
7.0%
↓ -52.1% 73th
FCF / Share Free cash flow per share
$0.12
↓ -24.8%
Long-Term Debt Long-term obligations
$101.56M
↓ -1.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
74
Returns
18
Financial Health
86
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters